Context: Nonfunctioning pituitary adenomas (NFPAs) are fairly common and require a multidisciplinary approach. Reliable markers of a clinically aggressive course are lacking. Medical treatment is not available, and transsphenoidal surgery is the preferred primary treatment.
N onfunctioning pituitary adenomas (NFPAs) are common intracranial neoplasms with an incidence of 1.8 per 100,000 per year, constituting close to half of all pituitary adenomas (1, 2) . NFPAs are usually benign, but they may show an aggressive clinical course with compression of surrounding structures, such as the optic chiasm, or invasion of the cavernous sinuses. The mainstay of treatment of symptomatic NFPAs is transsphenoidal surgery, with adjuvant radiation therapy for subgroups of tumors that show aggressive clinical behavior (3) . So far, there is no international consensus on how to follow up on patients with NFPAs, and reliable markers of tumor aggressiveness are lacking (4, 5) .
Medical treatment is not available as an alternative therapy for NFPAs. For functioning adenomas, two drug groups targeting the somatostatin receptors (SSTRs) and dopamine receptor are available (3) . SSTRs are G protein2coupled receptors located in the cell membrane. Five subtypes have been described (1) (2) (3) (4) (5) , and the pituitary gland expresses all but SSTR4 (6) . SSTR2 and SSTR5 are highly expressed in somatotroph adenomas and in thyrotroph adenomas (7, 8) , whereas SSTR5 is the most abundant in corticotroph adenomas (9) . Lactotroph adenomas express SSTR5, SSTR2, and SSTR1 (7), but activation of the dopamine receptor results in the most dominant inhibition of adenoma proliferation and function and is therefore the preferred target for medical treatment (10, 11) . SSTR3 has been shown to be the most abundant SSTR in NFPAs in several studies, whereas the expression of the remaining SSTRs has varied (12) (13) (14) .
Estrogen and progesterone receptors (ERs and PRs) are nuclear steroid hormone receptors found in normal pituitary tissue (15, 16) . There are two classes of ERs, ERa and ERb, both involved in growth and differentiation of several types of tissue (17) . The PR exists in two main isoforms: PRA and PRB. PRB is an activator of progesterone-dependent genes, and PRA inhibits the effect of PRB (18) . Although the PR has been thoroughly studied for its effects on proliferation and cell survival in breast cancer (19) , little is known about its function in the pituitary.
The aggressiveness of pituitary adenomas has been associated with a less-differentiated phenotype with loss of the cell adherence protein E-cadherin (20) (21) (22) . The expression of receptors in functioning pituitary adenomas has also been correlated to a clinically aggressive course (23) . So far, no link has been demonstrated between the distribution of SSTRs and clinical factors of aggressiveness in NFPAs (12, 14) .
In this study, we investigated the distribution of SSTRs 1, 2, 3, and 5 together with ERa and PR in a wellcharacterized cohort of clinically determined NFPAs.
Our aim was to map the receptor pattern in different subgroups of tumors and to link this pattern to variables of tumor aggressiveness.
Methods

Patients
Frozen tissue and formalin-fixed, paraffin-embedded tissue samples from the primary operation were available for 106 (37 females) and 145 (53 females) patients, respectively. In 94 of these patients, both frozen tissue and paraffin-embedded samples were available. Immunohistochemistry (IHC) classification was missing for five patients. All included patients underwent surgery between 1987 and 2009 at the same tertiary referral center. The patient records were investigated for information about hormone overproduction, and all tumors were clinically classified as nonfunctioning at the time of surgery. Patient information from before 2004 was retrieved mainly from archived paper records. One tumor showed transition from a clinically determined NFPA to a thyrotropin-producing adenoma 8 years after the primary operation.
New interventions, both radiation and surgery, during the first 12 months after the primary surgery were included as part of the primary intervention.
The study was approved by the regional ethics committee and hospital authority. Informed consent was obtained from all living patients.
Histopathology and IHC
The original hematoxylin and eosin2stained sections from all the tumors were reviewed to confirm the presence of pituitary adenoma tissue. Areas of representative tumor tissue were selected for tissue microarrays (TMAs). TMAs contained replicate 1-mm cores from formalin-fixed, paraffin-embedded tissue samples.
IHC classification of the pituitary adenomas was based on the expression of anterior pituitary lobe hormones and the transcriptional factors PIT1 and SF1, as previously described (24, 25) . Tumor tissue from a growth hormone2producing adenoma was used as a positive control for PIT1, and tumor tissue from a gonadotroph adenoma as a positive control for SF1. Sections from the recently constructed TMAs containing tumor tissue from tumors operated on between the second half of 2007 and 2009 were immunostained in a DAKO Autostainer Link 48 using the anti-follicle-stimulating hormone (DAKO, monoclonal, Clone C10, Code M3504), anti-luteinizing hormone (DAKO, monoclonal, Clone C93, Code M3502), and anti-thyrotropin (Novocastra, monoclonal, Clone QB2/6). The antibodies toward growth hormone, prolactin, adrenocorticotropin, and a subunit were unchanged. Normal pituitary tissue from the anterior pituitary gland was used as a positive control. TMAs from before mid-1997 (n = 12) were fixed in glutaraldehyde and were not used for IHC staining for the receptors presented in this study.
Monoclonal antibodies used to detect SSTRs were used according to previously described protocols (26) .
ERa was detected using monoclonal, ready-to-use antibody clone SP1 (Ventana-Roche). PR was detected using monoclonal, ready-to-use antibody clone 1E2 (Ventana-Roche), which detects the A and B forms of the PR. Both analyses were performed in Ventana BenchMark Ultra after CC1 (Cell Conditioning Solution) pretreatment, with 16-minute incubation with the primary antibody and using the UltraView Universal detection kit. Tissue from ductal mammary carcinoma served as a positive control. The negative controls in all the analyses were obtained by omitting the primary antibody.
Both the SSTRs and the ER and PR were scored using the immunoreactive score (IRS) as previously described (26, 27) . For some of the analyses, the IRS was graded as a negative score (IRS 0 to 1), low score (IRS 2 to 3), medium score (IRS 4 to 8), or high score (IRS 9 to 12) (12). IRS was performed by the same pathologist (O.C.-B.), who was blinded to the clinical data.
Quantitative reverse transcription polymerase chain reaction
Surgical specimens from pituitary adenomas were collected in the operating room as soon as possible after resection and kept frozen at 280°C. RNA isolation and quantitative reverse transcription polymerase chain reaction (RT-qPCR) were performed as described (28) . Primer pairs for the different receptors are listed in the supplemental file.
All RT-qPCR results were standardized against the geometric mean of two reference genes (GADPH and ALAS1), as validated in a previous study (28) .
Statistics
Statistical analyses for group comparisons were performed with x 2 and Fischer's exact test for nominal data and with the Mann-Whitney U and Kruskal-Wallis tests for all continuous data. The Spearman rank correlation coefficient was used for correlation analyses. Kaplan-Meier analyses with the log-rank test were performed to estimate and test for group differences in time to reintervention and follow-up time. Group differences were considered statistically significant at the 5% significance level. All statistical tests were two-sided tests.
To evaluate the potential for predicting the probability of reintervention on the basis of ERa status and age in male patients with gonadotroph adenomas, we randomly split this subgroup into training and test data sets (n = 52 and n = 19, respectively). A binary logistic regression model for reintervention was fitted on the training data, with ERa [present (IRS .1) or not present (IRS 0 to 1)] and age as covariates. The corresponding linear predictor (LP) was calculated from the estimated b-coefficients for age and ERa +/2 from the regression model using the formula LP = 6.527 + (20.111 3 age) + (22.064 3 ER +/2 ). It was then used to compute the predicted probability for reintervention in the test data using the formula PP = exp(LP)/[1 + exp(LP)].
When SSTR2 (which was positively correlated to ERa in men) was included in the prediction model for reintervention, it was not significant (B = 20.703; P = 0.39). SSTR2 also worsened the prediction performance of the regression model in the test data (misclassification proportion was 0.16 compared with 0.11 in the model without SSTR2; with one more false negative). SSTR2 was therefore kept out of the analyses. The statistical software SPSS version 24 was used for all analyses.
Results
Of the 164 patients included, 58 needed reintervention (reoperation or radiation), nine patients (three females) received radiation as their first reintervention and eight patients received radiation after reoperation (Table 1) . We did not find a difference in IRSs of the receptors according to modality of secondary intervention (data Median and interquartile ranges are given for all continuous data. The IRS is given for SSTR1, SSTR2, SSTR3, SSTR5, ERa, and PR (range, 0 to 12) and is the product of staining intensity (0 to 3) multiplied by the proportion of cells staining for the receptor (0 to 4). Paraffin-embedded tissues for immunohistochemistry analyses were available for 145 tumors in total. Analyses of low quality were excluded. a Age in years at primary operation.
b Early reintervention ,12 months after primary surgery is not included as reoperation or radiation. Radiation as both secondary and tertiary reintervention is included in the analyses. One patient underwent reoperation after secondary radiation. c SSTR1 range: women, 0 to 6, and men, 0 to 3.
d There was no sex difference between any of the receptors when premenopausal woman (age ,51 years) were excluded from the analyses.
not shown). Men and women were equal according to the rate of reintervention and IHC subtypes (Tables 1 and 2) , also when premenopausal women (,51 years of age) were excluded (29) . Eleven patients (three females) needed early reintervention (radiation in seven patients) less than 12 months after primary surgery (six gonadotroph, two corticotroph, two lactotroph, and one nullcell adenomas). Four patients died in relation to surgery or during convalescence. Most of the tumors were gonadotroph adenomas (74.4%). Only a few tumors stained for prolactin (n = 5), glycoprotein hormone a subunit (n = 2), growth hormone (n = 1), or multiple hormones (n = 2). These were excluded from the comparison between subtypes because of the small numbers. We found that null-cell adenomas had a higher rate of radiation therapy than the gonadotroph subgroup, although the numbers were small. Patients with corticotroph adenomas were significantly younger at the primary operation than patients with both gonadotroph and null-cell adenomas (Table 2) .
SSTR3 was abundantly expressed in NFPAs
SSTR3 was expressed abundantly across all subtypes in the IHC analyses. Most tumors showed a negative or Data are given for three subgroups of NFPAs (gonadotroph, corticotroph, and null-cell adenomas). The remaining tumors (n = 15) are plurihormonal (n = 2), lactotrophs (n = 5), somatotroph (n = 1), stains for alpha subunit (n = 2), or lacked immunohistochemistry classification (n = 5).
Immunoreactive score is given for all receptors (range, 0 to 12) and is the product of staining intensity (0 to 3) multiplied by the proportion of cells staining for the receptor (0 to 4). Median and interquartile range are given for all receptors. The Kruskal-Wallis test was used for group comparison. Post hoc tests were performed with the Mann-Whitney U test. Tissue from the primary operation was available for 145 tumors (10 of these from other subclasses). Samples were not included when the quality of the analyses was insufficient. a Age in years at primary surgery.
low IRS for SSTR1 and SSTR5 [ Fig. 1(a) ; Table 2 ]. SSTR3 and ERa showed the highest relative messenger RNA (mRNA) expression levels, whereas SSTR5 and SSTR1 showed low relative mRNA expression levels in RTqPCR analyses [ Fig. 1(b) ]. Gonadotroph, corticotroph, and null-cell adenomas resembled each other in membrane receptor staining, with a high IRS for SSTR3 and a negative or low IRS for SSTR1 and SSTR5 ( Table 2 ). The gonadotroph adenomas showed a higher relative mRNA expression level of SSTR3 by RT-qPCR analysis than the two other subtypes (median, respectively) (Supplemental Material). Corticotroph and gonadotroph adenomas did not stain for SSTR1, whereas a few null-cell adenomas did. Null-cell adenomas did not stain for SSTR2. Gonadotroph adenomas showed a higher IRS for ERa than the two other subtypes, though approximately half of the tumors (58%) presented negative staining (IRS, 0 to 1). Corticotroph adenomas had a higher IRS for SSTR5 than gonadotroph adenomas and a higher IRS for SSTR2 than null-cell adenomas (Table 2) .
Male patients had a lower IRS for SSTR1 and a higher IRS for PR than female patients (Table 1) . However, only two male and four female patients had tumors presenting SSTR1. The difference in PR was not present in The mRNA quantity of SSTR1, SSTR2, SSTR3, SSTR5, ERa, and PR divided by the geometric mean of two previously validated reference genes (ALAS1 and GAPDH) (28) for tumors with available frozen tissue (n = 106). Each bar represents the median with the IQR, and the whiskers represent the 2.5 and 97.5 percentiles. The y-axis is presented with log10 transformation after adding an offset of 0.001. Statistics were obtained using the Wilcoxon signed rank test. SSTR1 and SSTR5 was sign lower than the other receptors all comparisons with P , 0.01. SSTR5 was slightly higher than SSTR1, P = 0.056. gonadotroph or null-cell adenomas but was significant in corticotroph adenomas [P = 0.03; women, median (IQR) = 1.5 (0 to 3.75); men, median (IQR) = 6 (3.5 to 7)]. In our cohort, the PR score was age dependent in women but not in men (r s = 0.39, P = 0.007 and r s = 20.03, P = 0.77). Examples of IHC staining are given in Fig. 2 .
Interreceptor correlation was sex dependent
There was a positive correlation between the relative mRNA expression levels and IRS for SSTR2 and ERa. The correlation between mRNA and IRS for SSTR3 was close to, but did not reach, significance (Table 3) . SSTR1 was taken out of the correlation analyses as there were only nine tumors with IRS .0.
We found a moderate statistically significant correlation between ERa and SSTR2 in both RT-qPCR and IHC analyses (Table 3) . However, when the sexes were analyzed separately, the correlation was not significant for women but was highly significant for men (IHC women: r s = 0.037, P = 0.8; IHC men: r s = 0.44, P , 0.001 and RT-qPCR women: r s = 0.22, P = 0.2; RT-qPCR men: r s = 0.42, P # 0.001).
There was a correlation between the IRSs for SSTR2 and SSTR5 (Table 3) . With division between the sexes, this correlation was present among men but not among women (IRS women: r s =0.17, P = 0.26; IRS men: r s = 0.23, P = 0.04). These findings were not present in the mRNA expression analyses. We did not find a correlation between ERa and SSTR5 (Table 3) for men or for women. The correlations between both SSTR2 and ERa, and SSTR2 and SSTR5 were still significant in men but were not significant in women when we investigated gonadotroph tumors only and when patients characterized as premenopausal women (age ,51 years) were excluded (data not shown).
The association between receptor distribution and aggressiveness was linked to sex
We did not find a relation between the staining grades of SSTR2, SSTR3, SSTR5, and PR and the rate of reintervention in men or women (data not shown). We found that the IRS of ERa was related to the rate of reintervention in men (P = 0.001), whereas this relation was not present in women (IRS negative: 7 (reintervention)/26 (total), low 4/12, medium 2/7, and high 0/2; P = 0.95).
The men presenting tumors with a negative ERa staining score (IRS, 0 to 1) had a higher rate of reintervention (25/ 51) than men with both low (1/15) and medium (3/20) IRSs for ERa (P = 0.003 and P = 0.01, respectively) in post hoc analyses. No men presented a high IRS for ERa in our cohort. The IRS for ERa was also associated with time to reintervention for men only (Fig. 3) . In the same manner, men presenting a negative ERa score (IRS, 0 to 1) had significantly shorter time to reintervention than men presenting low and medium ERa scores (P = 0.005 and P = 0.04, respectively). Men and women had the same rate of reintervention, with comparable follow-up time (Table 1) . These sex-dependent associations between ERa and rate of and time to reintervention were also present when only gonadotroph tumors were included and also when premenopausal women (,51 years of age) were excluded from the analyses (data not shown).
We evaluated the prognostic value of ERa status [present (IRS, .1) or not present (IRS, 0 to 1)] for reintervention in men with gonadotroph adenomas. Age was included in the regression analysis, whereas patients who went through reintervention were younger at the primary surgery [median, 53 years (IQR, 44.8 to 61.3 years)] than those who did not [median, 61 years (IQR, 51 to 72 years; P , 0.001)].
We randomly split the data into age-matched training and test data sets. A prediction model for reintervention fitted on the training data was evaluated on the test data with predicted vs observed reintervention. The presence of ERa combined with age served as a good prediction model for reintervention, with only two falsely predicted reinterventions in the test data, whereas 12 and five patients were correctly predicted to the no reintervention and reintervention groups, respectively (P = 0.002). Receiver operating characteristic analysis for the predicted probabilities gave a high area under the curve (AUC) of 0.9. The cutoff for age at 60 years gave a distribution of predicted reintervention identical to that for age as a continuous variable.
Discussion
In this study of NFPAs, we found that the SSTR staining patterns in the sexes resembled each other with a high IRS for SSTR3 and an absent or low IRS for SSTR1, SSTR2, and SSTR5. Patients with corticotroph adenomas were younger than patients with gonadotroph and null-cell adenomas. SSTR2 and ERa showed a sex-dependent positive correlation in both IHC and mRNA analyses. A negative IRS (IRS 0-1) for ERa was associated with a higher rate of and shorter time to reintervention in male patients only. The absence of ERa together with younger age appeared to predict the risk of reintervention in men with gonadotroph adenomas.
NFPAs express SSTR subtypes in various patterns. Several studies have shown that SSTR3 is the most abundant of the SSTRs in NFPAs when analyzed both at the mRNA level and by IHC, whereas other SSTRs have shown variable expression (12) (13) (14) . Our results add to these findings, supporting the potential for SSTR3 as a target for medical treatment of NFPAs. Stimulation of Figure 3 . Time from primary surgery to reintervention according to IRSs for ERa in men and women. An event was defined as secondary surgery or radiation more than 12 months after the primary surgery. The time course was censored when the patient ended follow-up for reasons other than reintervention: P = 0.65 (women), P = 0.004 (men). Post hoc analyses revealed a significant difference between negative (IRS, 0 to 1) and low (IRS, 2 to 3) ERa scores (P = 0.005) and negative and medium (IRS, 4 to 8) ERa scores (P = 0.04) for men. There was no significant difference between low and medium ERa scores (P = 0.32) for men. Patients who died in relation to surgery or during convalescence (n = 4) were taken out of the Kaplan-Meier analysis.
SSTR3 is known to have apoptotic and antiproliferative effects in endothelial cells (30, 31) . Previous studies have associated the ligand-independent presence of SSTR3 with a reduced level of hormone secretion in somatotroph and corticotroph cell lines (32, 33) . So far, no effective medical treatment of NFPAs has been established, though a clinical trial on pasireotide, an SSTR-agonist, is ongoing (ClinicalTrials.gov identifier: NCT01283542).
A recent study found equal and abundant expression of SSTR2 among gonadotroph and null-cell adenomas when the proportion of positively staining cells was investigated (14) . In our cohort, null-cell adenomas did not stain for SSTR2 ( Table 2 ). The proportion of null-cell adenomas in our cohort was small compared with the proportion in the study by Ramirez et al. (14) . In the current study, adenomas not staining for pituitary hormones but staining for transcription factors SF1 and PIT1 were categorized as gonadotroph adenomas and lacto-, somato-, or thyrotroph adenomas, respectively. These subgroups showed a higher presentation of SSTR2 than null-cell adenomas did, which may explain the discrepancy in findings between these two studies.
The IRS of SSTR5 was higher in corticotroph adenomas than in the gonadotroph subgroup, which did not stain for SSTR5 (Table 2) . Gonadotroph adenomas were previously found not to stain for SSTR5 (12) , whereas functioning corticotroph adenomas expressed SSTR5 (9, 34) . It has been suggested that the different subgroups of NFPAs resemble the clinical features of their functioning counterparts (35) , though the expression of receptors was not investigated in the previous analysis.
The gonadotroph subgroup showed the highest IRS for ERa, though the score in general was low (Table 2) . It has been shown that gonadotroph adenomas stain for ERa at low levels (36) . ERs have varied in expression between IHC subtypes of pituitary adenomas in previous studies and were lowest in corticotroph tumors (35, 37) . The ERa is known to be a transcription factor in the gonadotroph and lactotroph cell lineage (35) , and it was barely detected in the subgroups of null-cell and corticotroph adenomas in the current study.
PR plays a role in cell proliferation and tumorigenesis (19) . We found that men had a higher IRS of PR than women in the IHC analysis (Table 1) . This difference was found in corticotroph but not gonadotroph or null-cell adenomas in subgroup analyses with and without premenopausal women (age ,51 years). Five of the six female patients with corticotroph adenomas were characterized as premenopausal, which may explain the difference in PR, whereas the PR IRS was age dependent in women but not in men. This also explains the age difference between the IHC subgroups; as five of six female patients with null-cell adenomas were categorized as postmenopausal (age .51 years). The difference in age between the subgroups might also explain the higher rate of radiation in the group of null-cell adenomas (Table 2 ). In addition, null-cell adenomas did not express SSTR2, SSTR5, or ERa. This subgroup was earlier described as poorly differentiated and more prone to show factors of aggressiveness than the other NFPA subgroups (35) . The corticotroph and null-cell subgroups in the present study were small, and the results should therefore be interpreted carefully.
We found a good correlation between IHC and the relative mRNA expression levels for some but not all receptors ( Table 3 ). Lack of correlation may be related to differences in the half-lives of protein and mRNA in vivo. An abundance of complex steps between transcription of mRNA and translation of protein have not been well defined and may contribute to the lack of correlation (38) .
The level of ERa (IRS and mRNA) was significantly correlated to the level of SSTR2 in men. Similar results have been presented previously for mRNA analyses, though not presenting sex differences (13) . Studies on breast cancer cells have shown that ER and SSTR2 expressions were correlated, and it has been suggested that estrogens regulate the level of SSTR2 through ERa activation (39, 40) . Some studies showed that men were more prone to develop NFPAs than women were, though little is known about the mechanisms involved (1, 2) . Approximately two-thirds of our cohort were men, comparable with the sex distribution in register-based studies (1, 2). However, knowledge about the mechanisms behind the sex differences is limited.
An association between the IRS of ERa and the rate of reintervention was found in men. A low ERa staining score has been associated with resistance to medical treatment in prolactinomas (41) . In contrast, Zhou et al. (42) found that ERa staining was significantly stronger in invasive than in noninvasive NFPAs; however, their IHC subgroup distribution differed markedly from that of the current study, with only two being silent gonadotroph adenomas. Also, invasiveness is not necessarily an indication for surgery or radiotherapy; hence, the groups compared will be different. Manoranjan et al. (37) found stronger immunoreactivity for ERa in macroadenomas than in microadenomas but lower ERa expression in invasive than in noninvasive pituitary adenomas. They did not present subgroup analyses for NFPAs, and their results are therefore not comparable to the results presented in this study.
In breast cancer cells, ERa-negative cells have been shown to often be E-cadherin negative (43) . Thus, the loss of E-cadherin has been associated with a less-differentiated phenotype for epithelial tumors (44) . The gene encoding E-cadherin (CDH1) has also been found to be silenced more often in ER-negative breast cancer than in ER-positive breast cancer, leading to lower levels of E-cadherin and a more aggressive phenotype (45) . Zhou et al. (42) found that E-cadherin and ERa were negatively correlated, with downregulated E-cadherin in invasive NFPAs.
The lack of reliable prognostic markers is a challenge in the follow-up of patients with NFPAs. We tested a prediction model for reintervention according to the presence of ERa and age in men with gonadotroph adenomas. Only two patients from the test data set were misclassified to the reintervention group. This indicates that the absence of ERa together with younger age might be a useful tool in predicting the risk of reintervention, but this warrants verification in systematic prospective studies. Interestingly, in their cohort of prolactinomas, Delgrange et al. (41) found that a low ERa IRS was more frequent in men than in women. Low ERa was also related to a clinically aggressive course, suggesting that loss of ERa is an indicator of poor prognosis in prolactinomas.
Limitations
This study was retrospective and lacked systematic inclusion of patients. The results should therefore be confirmed in systematic prospective studies. The reintervention variable comprised both secondary surgery and radiation. Indications for secondary intervention might be due to several factors, such as the preoperative size of the tumor; level of residual tumor after primary surgery, which again might depend on the skills of the surgeon; perioperative conditions; or the patient's condition. We therefore assumed that the earliest reinterventions (,12 months) were due to inadequate resection at the primary surgery and were a part of primary treatment. The largest tumors at presentation might demand several surgical interventions and radiation therapy as primary therapy, which was not considered to be reintervention.
The classification of NFPAs has become increasingly specific with staining for both transcription factors and pituitary hormones. As a result, the number of null-cell adenomas has been reduced (35) . This specific classification makes it difficult to compare the subgroup analyses with previous studies, in which classification did not include transcription factors. Antibodies toward T-pit were not available for this study, so this was not included in our IHC analyses. The null-cell and corticotroph subgroups were already small in our cohort, and not staining for T-pit might have obscured differences between the two groups.
Conclusion
We found that SSTR3 was abundantly expressed in NFPAs and might therefore be a potential target for medical treatment. The IRS of ERa was linked to the IRS of SSTR2 in male patients but not in female patients. A negative IRS for ERa was associated with a higher rate of reintervention in male patients only. This might point to a relationship among aggressiveness, differentiation of tumor, and sex in NFPAs. In addition, the absence of ERa together with young age might serve as a predictor for tumor recurrence in groups of NFPA patients. Our findings require further investigation by in vitro studies in cell cultures and systematic prospective studies.
